About Us
Careers
Partner with us
Forgot password?
Sign in
Login
Login
Email
Password
Forgot your password?
Join VuMedi
Select specialty
Your main specialty
Adult & Family Medicine
Allergy, Asthma, Immunology
Anesthesiology
Cardiovascular
Dental
Dermatology
Emergency Medicine
Endocrinology
Gastroenterology & Hepatology
General Surgery
Hematology & Oncology
Infectious Disease
Medical Genetics
Nephrology
Neurology
Neurosurgery
Obstetrics/Gynecology
Ophthalmology
Oral Maxillofacial
Orthopaedics
Otolaryngology
Pathology
Pediatrics
Physical Medicine & Rehab
Plastic Surgery
Podiatry
Preventive Medicine
Psychiatry
Pulmonology
Radiation Oncology
Radiology
Rheumatology
Urology
First name
Last name
Email
Choose Password
Society of Hematologic Oncology Seventh Annual Meeting (SOHO 2019)
https://www.soho2019.com/
Hodgkin Lymphoma
Multiple Myeloma
Chronic Lymphocytic Leukemia
Meet The Professor Sessions
Chronic Myeloid Leukemia
Myeloproliferative Neoplasms
Breakfast With The Expert
Independent Satellite Symposium
Plenary Sessions
Evolving Practices in AML: A Case-based Guide to New and Emerging Treatment Options
Acute Lymphoblastic Leukemia
Myelodysplastic Syndromes
Acute Myeloid Leukemia
Indolent B-cell Lymphoma
Mantle Cell Lymphoma
Aggressive B-cell Lymphoma
T-cell Lymphoma
Cellular Therapy
Next Questions
Events
Playback speed
0.5x
0.75x
1x (Normal)
1.25x
1.5x
1.75x
2x
10 seconds
Therapeutic Innovations in CML: Reducing Toxicity w/ Optimized Frontline Dosing or Programmed Dose Reductions, New ABL1 TKI Asciminib Is Very Promising
By
Society of Hematologic Oncology Seventh Annual Meeting (SOHO 2019)
FEATURING
Michael Deininger
By
Society of Hematologic Oncology Seventh Annual Meeting (SOHO 2019)
FEATURING
Michael Deininger
7 views
November 18, 2019
0 Comments
Login to view comments.
Click here to Login
Featured Video
06:51
Insights from 2023 ASH Annual Meeting
ASH 2023 Insights: "Prevalence and Prediction of Ruxolitinib Tr…
Feat.
D. Tremblay
Featured Video
15:14
Icahn School of Medicine at Mount Sinai
Safety Profile of Ruxolitinib in Patients With MF
Feat.
D. Tremblay
Chronic Myeloid Leukemia
17:08
Society of Hematologic Oncology Seventh Annual Meeting (SOHO 2019)
CML State of the Art 2019: 2nd Generation TKIs Improve Molecular Out…
Feat.
J. Cortés
15:28
Society of Hematologic Oncology Seventh Annual Meeting (SOHO 2019)
Therapeutic Innovations in CML: Reducing Toxicity w/ Optimized Front…
Feat.
M. Deininger
18:37
Society of Hematologic Oncology Seventh Annual Meeting (SOHO 2019)
Impact of Depth and Duration of Response of TFR in CML: Current Reco…
Feat.
D. Rea
12:22
Society of Hematologic Oncology Seventh Annual Meeting (SOHO 2019)
Impact of Comorbidities in Treatment Choice of CML: TKI Toxicities N…
Feat.
T. Hughes
15:19
Society of Hematologic Oncology Seventh Annual Meeting (SOHO 2019)
29 y/o Male w/ CML: Allograft vs. 3rd Line Therapy - Transplant Is A…
Feat.
M. Mauro
08:01
Society of Hematologic Oncology Seventh Annual Meeting (SOHO 2019)
CML-044 ENESTop 192-Weeks Results on Treatment-Free Remission in Chr…
Feat.
T. Hughes
13:11
Society of Hematologic Oncology Seventh Annual Meeting (SOHO 2019)
Phase 1 CML-041 Results on Combination of Asciminib, a Novel and Spe…
Feat.
M. Talpaz
